Endotypes in Immune Mediated Drug Reactions: Present and Future of Relevant Biomarkers. An EAACI Task Force Report
Allergy · 2025-07 · 80 (7) · 1831-1847
DOI: 10.1111/all.16576 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergy, online erschienen am 07.05.2025. Verfasst von C Mayorga und 7 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Unit, Hospital Regional Universitario de Málaga and Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Platafo…. Hauptthemen laut MEDLINE: Biomarkers, Drug Hypersensitivity. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 108 Literaturangaben. Gefördert von: European Academy of Allergy and Clinical Immunology.
Abstract (Originalsprache)
Drug‐induced immune reactions are an important burden for patients and health systems. They can be classified into immediate‐drug hypersensitivity reactions (IDHRs) and delayed‐DHRs (DDHRs) based on their phenotype. Drugs do not always behave as allergens and need to bind to proteins, forming adducts. Therefore, IDHRs can be classified as antigenic (IgE, and IgG mediated) and nonantigenic immune responses (complement activation‐[CARPA], mas‐related G‐protein coupled receptor member X2 [MRGPRX2], cyclooxygenase [COX]‐1 and cytokine release reactions [CRRs]). DDHRs are even more complex due to the different cell subsets and mechanisms involved, showing both antigenic and nonantigenic immune responses too. Since different endotypes result in similar phenotypes, the establishment of specific biomarkers is essential for an accurate diagnosis, with important relevance for the management of patients, as well as for risk stratification. The biomarkers of clinical utility are skin tests, specific IgE (sIgE), tryptase, and some HLA‐DR genotyping. The diagnostic performance depends on the responsible drug. This review highlights that, unfortunately, most biomarkers have not gone beyond analytic or clinical validity. It is therefore important to set up multicentre translational studies to advance the validation process towards reaching a clinical utility phase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Unit, Hospital Regional Universitario de Málaga and Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain.
- RICORS Red De Enfermedades Inflamatorias (REI), Madrid, Spain.
- Immunology Department, IIS-Fundacion Jimenez Diaz, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.
- Ankara University School of Medicine, Dept of Immunology and Allergy, Private clinic, Ankara, Turkey.
- Department of Internal Medicine, University of Genova, Genova, Italy.
- Allergology and Clinical Immunology Unit, San Bartolomeo Hospital, Sarzana, Italy.
ORCID-Profile: C Mayorga, R Fernandez-Santamaria, G E Çelik, M Labella, G Murdaca, M Sokolowska, D Naisbitt, V Sabato
Förderung
- European Academy of Allergy and Clinical Immunology
Zitieren
APA
Mayorga, C., Fernandez-Santamaria, R., Çelik, G. E., Labella, M., Murdaca, G., Sokolowska, M., Naisbitt, D., & Sabato, V. (2025). Endotypes in Immune Mediated Drug Reactions: Present and Future of Relevant Biomarkers. An EAACI Task Force Report. Allergy, 80(7), 1831-1847. https://doi.org/10.1111/all.16576
Vancouver
Mayorga C, Fernandez-Santamaria R, Çelik GE, Labella M, Murdaca G, Sokolowska M, et al. Endotypes in Immune Mediated Drug Reactions: Present and Future of Relevant Biomarkers. An EAACI Task Force Report. Allergy. 2025;80(7):1831-1847. doi:10.1111/all.16576
BibTeX
@article{Mayorga2025,
author = {Mayorga, C and Fernandez-Santamaria, R and Çelik, G E and Labella, M and Murdaca, G and Sokolowska, M and Naisbitt, D and Sabato, V},
title = {Endotypes in Immune Mediated Drug Reactions: Present and Future of Relevant Biomarkers. An EAACI Task Force Report},
journal = {Allergy},
year = {2025},
volume = {80},
number = {7},
pages = {1831--1847},
doi = {10.1111/all.16576}
}
EUVIMED